Management Team

Mr. Lin has worked at several financial institutions with management roles since 2013, including Liye Pharmaceutical Co., Ltd, Shanxi Liye Pharmaceutical Co., Ltd, Shenzhen Hongbangsheng Asset Management Co., Ltd, ChinaLin Capital Investment Co., Ltd and ChinaLin Securities Co., Ltd.

Mr. Chen PJ graduated from Massachusetts Institute of Technology, and has worked at several well-known international pharmaceutical corporations with leading R&D roles, including senior vice president of global clinical development of APRINOIA Therapeutics, the general manager of United Biopharmaceuticals and head of clinical management of PPD North Asia.

Dr. Erol Onel graduated from the Albert Einstein College of Medicine in New York, and completed a Urology residency in Connecticut and a fellowship in Illinois. He most recently served at Heron Therapeutics, where he helped guide their bupivacaine/meloxicam combination product to approval for post-operative pain control and opioid reduction in the United states and Europe. Prior to that, he was at Pacira Pharmaceuticals, where he led the team that gained approval of their long-acting liposomal bupivacaine product for post-operative pain control. Dr. Onel has authored over 50 scientific papers, presentations and book chapters.

Dr. Lee Chen graduated from University of Maryland School of Pharmacy, and is specialized in the operation and management of innovative drug formulation development projects. Dr. Chen has participated in publication of more than 20 scientific papers and presentations.